Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Objective: Although aripiprazole has been widely used to treat various psychiatric disorders, little is known about the adequate dosage for Asian patients in clinical practice. Hence, we evaluated the initial and maximum doses of aripiprazole from 2004 to 2014 to estimate the appropriate dosage for Korean psychiatric inpatients in clinical practice. Methods: In this retrospective study, we reviewed the medical records of patients who were hospitalized in five university hospitals in Korea from March 2004 to December 2014. The psychiatric diagnosis according to the text revision of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition during index hospitalization and the initial and maximum doses of aripiprazole were evaluated. Results: There were 74 patients in Wave 1 (2004-2006), 201 patients in Wave 2 (2007-2010), and 353 patients in Wave 3 (2011-2014). The initial doses of aripiprazole in all diagnostic groups were significantly lower in Wave 3 than in Wave 2. The maximum doses of aripiprazole in each diagnostic group were not significantly different among Waves 1, 2, and 3. Conclusion: The relatively low initial doses of aripiprazole documented in our study may reflect a strategy by clinicians to minimize the side effects associated with aripiprazole use, such as akathisia.
Abstract
Objective: Although aripiprazole has been widely used to treat various psychiatric disorders, little is known about the adequate dosage for Asian patients in clinical practice. Hence, we evaluated the initial and maximum doses of aripiprazole from 2004 to 2014 to estimate the appropriate dosage for Korean psychiatric inpatients in clinical practice. Methods: In this retrospective study, we reviewed the medical records of patients who were hospitalized in five university hospitals in Korea from March 2004 to December 2014. The psychiatric diagnosis according to the text revision of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition during index hospitalization and the initial and maximum doses of aripiprazole were evaluated. Results: There were 74 patients in Wave 1 (2004-2006), 201 patients in Wave 2 (2007-2010), and 353 patients in Wave 3 (2011-2014). The initial doses of aripiprazole in all diagnostic groups were significantly lower in Wave 3 than in Wave 2. The maximum doses of aripiprazole in each diagnostic group were not significantly different among Waves 1, 2, and 3. Conclusion: The relatively low initial doses of aripiprazole documented in our study may reflect a strategy by clinicians to minimize the side effects associated with aripiprazole use, such as akathisia.
참고문헌 (19)
- Di Sciascio G, "Aripiprazole : from pharmacological profile to clinical use", Neuropsychiatr Dis Treat, 11, pp.2635~2647 (2015)
- Stip E, "Aripiprazole in schizophrenia and schizoaffective disorder: a review", Clin Ther, 32(Suppl 1), pp.S3~S20 (2010)
- Moro MF, "Evaluating aripiprazole as a potential bipolar disorder therapy for adults", Expert Opin Investig Drugs, 23, pp.1713~1730 (2014)
- Pae CU, "Aripiprazole as adjunctive therapy for patients with major depressive disorder : overview and implications of clinical trial data", CNS Drugs, 25, pp.109~127 (2011)
- Farmer CA, "Aripiprazole for the treatment of irritability associated with autism", Expert Opin Pharmacother, 12, pp.635~640 (2011)
- Zheng W, "Aripiprazole for Tourette's syndrome : a systematic review and meta-analysis", Hum Psychopharmacol, 31, pp.11~18 (2016)
- Khanna P, "Aripiprazole versus other atypical antipsychotics for schizophrenia", Cochrane Database Syst Rev, (1), pp.CD006569~ (2014)
- Hartung DM, "Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients", J Clin Psychiatry, 69, pp.1540~1547 (2008)
- Citrome L, "Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder", Schizophr Res, 108, pp.238~244 (2009)
- Citrome L, "Dosing of second-generation antipsychotic medication in a state hospital system", J Clin Psychopharmacol, 25, pp.388~391 (2005)
- Pae CU, "A review of the safety and tolerability of aripiprazole", Expert Opin Drug Saf, 8, pp.373~386 (2009)
- Mace S, "Aripiprazole : dose-response relationship in schizophrenia and schizoaffective disorder", CNS Drugs, 23, pp.773~780 (2009)
- Kane JM, "Extrapyramidal side effects are unacceptable", Eur Neuropsychopharmacol, 11(Suppl 4), pp.S397~S403 (2001)
- Ghaemi SN, "Extrapyramidal side effects with atypical neuroleptics in bipolar disorder", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.209~213 (2006)
- Kane JM, "Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder:a post hoc analysis of pooled data from short- and long-term aripiprazole trials", J Psychopharmacol, 24, pp.1019~1029 (2010)
- Marder SR, "Aripiprazole in the treatment of schizophrenia:safety and tolerability in short-term, placebocontrolled trials", Schizophr Res, 61, pp.123~136 (2003)
- Miller CH, "Risk factors for the development of neuroleptic induced akathisia", Eur Neuropsychopharmacol, 7, pp.51~55 (1997)
- Basu R, "Dose-dependent rapid-onset akathisia with aripiprazole in patients with schizoaffective disorder", Neuropsychiatr Dis Treat, 2, pp.241~243 (2006)
- Nelson JC, "Safety and tolerability of adjunctive aripiprazole in major depressive disorder : A pooled post hoc analysis(studies CN138-139 and CN138-163)", Prim Care Companion J Clin Psychiatry, 11, pp.344~352 (2009)